CNS Pharmaceuticals (CNSP) Cash Flow: Operating & Free Cash Flow

CNS Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for CNS Pharmaceuticals, Inc. (CNSP) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2024	FY 2023	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Mar 2025	Dec 2024	Mar 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Operating Activities
Net Income	-15.85	-14.86	-14.86	-18.85	-18.85	-15.27	-14.50	-9.46	-3.88	-7.39	-0.22
Depreciation & Amortization	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.00	0.00	0.00
Stock Based Compensation	0.19	0.84	0.84	1.01	1.01	1.20	1.72	1.29	0.48	0.11	0.12
Change in Working Capital	1.85	-3.69	-3.69	3.70	3.70	3.16	-0.78	0.83	-0.43	0.08	0.05
Change in Accounts Payable	0.00	-3.63	-3.63	1.32	1.32	1.70	1.04	0.66	0.15	0.07	0.06
Change in Other Working Capital	1.85	-0.06	0.60	2.38	2.38	1.46	-1.82	0.18	-0.58	0.01	-0.01
Other Operating Activities	0.00	0.60	0.60	0.00	0.00	0.34	0.00	0.00	0.27	6.48	-0.06
Net Cash from Operating Activities	-13.81	-17.11	-17.11	-14.14	-14.14	-10.56	-13.54	-7.32	-3.55	-0.72	-0.11
Investing Activities
Capital Expenditures	-0.02	0.00	0.00	0.00	0.00	0.00	-0.01	-0.02	-0.02	0.00	0.00
Net Cash from Investing Activities	-0.02	0.00	0.00	0.00	0.00	0.00	-0.01	-0.02	-0.02	0.00	0.00
Financing Activities
Debt Repayment	-0.30	-0.30	-0.30	-0.44	-0.44	-0.43	-0.48	-0.04	-0.04	0.30	0.12
Common Stock Issued	14.05	23.38	23.38	2.32	5.28	16.04	4.65	14.22	10.29	0.39	0.10
Common Stock Repurchased	0.00	0.00	-	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00
Other Financing Activities	0.82	-0.05	-0.07	2.76	-0.20	0.00	0.33	-0.05	0.00	0.47	0.00
Net Cash from Financing Activities	14.57	23.03	23.03	4.64	4.64	15.61	4.51	14.13	10.26	1.16	0.22
Summary
Net Change in Cash	0.74	5.91	5.91	-9.51	-9.51	5.05	-9.03	6.80	6.69	0.44	0.11
Cash at Beginning of Period	6.46	0.55	0.55	10.06	10.06	5.00	14.04	7.24	0.56	0.11	0.00
Cash at End of Period	7.20	6.46	6.46	0.55	0.55	10.06	5.00	14.04	7.24	0.56	0.11
Free Cash Flow	-13.83	-17.12	-17.12	-14.14	-14.14	-10.56	-13.54	-7.34	-3.57	-0.72	-0.11
Supplemental Disclosures
Interest Paid	-	-	0.01	-	0.01	0.01	0.01	0.00	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About CNS Pharmaceuticals Cash Flow

What is CNS Pharmaceuticals's free cash flow?

CNS Pharmaceuticals had negative free cash flow of $13.83M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$13.81M minus $18.18K of capital expenditures.

How much does CNS Pharmaceuticals spend on capital expenditures?

CNS Pharmaceuticals spent $18.18K on capital expenditures in fiscal 2025, compared with $4.19K a year earlier.

Does CNS Pharmaceuticals pay dividends or buy back shares?

Yes. In fiscal 2025 CNS Pharmaceuticals returned $2.04K in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition